To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy. In patients with inflammatory rheumatic disorders requiring prolonged glucocorticoid therapy, such tool could be useful to adapt first-line treatment decisions (in daily practice and in future clinical trials). The main objective of the study is to identify routine clinical, biological and DXA baseline characteristics predictive of the occurrence of clinically relevant complications of glucocorticoid therapy at 1 year, in order to propose a predictive score.
Study Type
OBSERVATIONAL
Enrollment
300
CHU d'Angers
Angers, France
CHRU de Brest
Brest, France
CHD Vendée
La Roche-sur-Yon, France
CH Le Mans
Le Mans, France
CH des Pays de Morlaix
Morlaix, France
CHU de Nantes - Service de Médecine interne
Nantes, France
CHU de Nantes - Service de Rhumatologie
Nantes, France
CHR d'Orléans
Orléans, France
<CHU de Poitiers
Poitiers, France
CHIC Quimper
Quimper, France
...and 2 more locations
Clinically relevant complication of glucocorticoid therapy
The occurrence of one or more clinically relevant complication of glucocorticoid therapy during the first year of treatment, according to the Glucocorticoid Toxicity Index (items and specific list).
Time frame: 1 year
Quality of life assessed through SF-36
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.